



# Perfluoroalkyl substances are inversely associated with coronary heart disease in adults with diabetes

Kyoko Honda-Kohmo<sup>a,b</sup>, Robert Hutcheson<sup>a</sup>, Kim E. Innes<sup>a</sup>, Baqiyah N. Conway<sup>a,c,\*</sup>

<sup>a</sup> Department of Epidemiology, West Virginia University, Morgantown, WV, USA

<sup>b</sup> Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>c</sup> Department of Community Health, University of Texas Health Science Center at Tyler, Tyler, TX, USA

## ARTICLE INFO

### Article history:

Received 1 November 2018

Received in revised form 29 January 2019

Accepted 12 February 2019

Available online 20 February 2019

### Keywords:

Diabetes

Coronary heart disease

Perfluoroalkyl substances

Perfluorooctanoic acid

Perfluorooctane sulfonate

Perfluorononanoic acid

## ABSTRACT

**Aims:** Perfluoroalkyl substances (PFAS) are environmentally and biologically persistent synthetic environmental contaminants linked to adverse health outcomes. Though null to modest inverse relationships between PFAS and coronary heart disease (CHD) have been reported, studies regarding relationships in high risk populations such as those with diabetes are sparse. We investigated the relationship of PFAS with CHD in persons with diabetes. **Methods:** Data on 5270 adults, aged  $\geq 20$  years, with diabetes were obtained from the C8 Health Project. Four PFAS were investigated separately: perfluorohexane sulfonate (PFHxS), perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS), and perfluorononanoic acid (PFNA).

**Results:** In logistic regression analyses adjusting for age, sex, diabetes duration, BMI, smoking, lipids, WBC, CRP, eGFR, uric acid, hemoglobin and iron, all PFAS were inversely associated with CHD, ORs (95% CIs): PFHxS; 0.72 (0.65–0.79), PFOA; 0.90 (0.81–0.96), PFOS; 0.90 (0.81–0.99), PFNA; 0.88 (0.76–1.02). Stratification by chronic kidney disease status revealed similar inverse relationships for those with and without chronic kidney disease. **Conclusions:** In this cross-sectional study of over 5000 adults with diabetes, PFAS showed inverse associations with CHD. These findings may, if confirmed in future studies, provide new physiologic understanding of CHD prevention strategies.

© 2019 Elsevier Inc. All rights reserved.

## 1. Introduction

Coronary heart disease (CHD) is the major cause of death in diabetes. In addition to traditional risk factors, common environmental exposures, including persistent environment contaminants, may also influence CHD risk. Perfluoroalkyl substances (PFAS) are a class of highly fluorinated chemicals, perfluorocarbons, with a wide variety of functional groups and industrial and consumer uses. PFAS contamination has raised public health concerns because these compounds are mobile and persistent in the environment, are readily absorbed into most vertebrate species, including humans, and have been linked to adverse health effects.<sup>1</sup>

In epidemiological studies, exposure to the common PFAS, perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS), has been weakly linked to higher cholesterol levels<sup>2,3</sup> and higher serum uric acid levels,<sup>4</sup> which are risk factors for CHD. However,

serum levels of these PFAS have also been inversely associated with obesity and C-reactive protein, a measure of systemic inflammation that has also been linked to CHD. Findings regarding the relationship of PFAS with diabetes have been mixed, with most studies suggesting no<sup>5,6</sup> or inverse associations,<sup>7–9</sup> while a recent prospective study found elevated risk of diabetes associated with PFOA and PFOS.<sup>10</sup> However, few studies have examined the relationship between PFAS and CHD, with most studies showing no association.<sup>2,11,12</sup>

The mixed findings concerning the relationship of PFAS with health outcomes may relate to the high oxygen carrying capacity of perfluorocarbons,<sup>13–16</sup> thus potentially mitigating any adverse effect they may have on vascular health via anti-hypoxia properties. Indeed, we have recently observed an inverse relationship between PFAS and progression of chronic kidney disease,<sup>17</sup> progression that is hypothesized to be due to chronic hypoxia.<sup>18–20</sup> This inverse relationship was stronger in persons with anemia or diabetes, a condition also characterized as a state of low grade chronic hypoxia.<sup>17</sup>

Studies on the relationship of PFAS and CHD among persons with diabetes are lacking. The objective of this cross-sectional study was to investigate the relationship of CHD to concentrations of four common PFAS in adults with diabetes. Our underlying hypothesis behind the analyses presented in this report is that the high oxygen carrying capacity of PFAS is protective against CHD.

Conflicts of interests: The authors have no conflicts of interest to declare.

\* Corresponding author at: Department of Community Health, School of Rural and Community Health, University of Texas Health Science Center at Tyler, 11937 US Hwy 271, Tyler, TX 75703-3154, USA.

E-mail address: [baqiyah.conway@uthct.edu](mailto:baqiyah.conway@uthct.edu) (B.N. Conway).

## 2. Materials and methods

### 2.1. Source of data

The C8 Health Project was created as part of a settlement after it was found that PFOA had contaminated the drinking water of six water districts in the mid-Ohio Valley in West Virginia and Ohio between 1950 and 2004. A post-hoc agreement between the settling parties of the class action lawsuit created the C8 Health Project, a community-based health survey designed to investigate the effects of exposure to PFOA-contaminated drinking water.<sup>21</sup> From August 2005 to August 2006, baseline data were gathered on 69,030 individuals working or living in the six PFOA-contaminated water districts, including those exposed to contaminated private-well drinking water. Estimated participation rate in the C8 Health Project among adult residents of the affected water districts was 81%.<sup>22</sup>

### 2.2. Clinical and biochemical analyses

The enrollment and data collection methods for the C8 Health Project have been described in detail previously.<sup>21</sup> The health survey collected a wide range of serum and anthropometric measures, as well as self-reported clinician diagnoses of medical conditions. Coronary heart disease diagnoses included self-report of clinician-based diagnosis of myocardial infarction, arteriosclerosis, and coronary artery disease check off boxes, and an opportunity to write out diagnoses in a drop down from “other heart disease” (specified by participants). Diabetes was also based on self-report of clinician diagnosis, and this field also included a drop down menu for the diabetes type and another drop down for the age at disease onset. We obtained institutional review board approval at West Virginia University for access to the C8 Health Project de-identified data for this study.

### 2.3. Subjects

There were 13,018 children and adolescents under the age of 20 years who were excluded from analysis. Of the remaining 58,712 study participants, 5296 reported a physician diagnosis of diabetes. Of the 5296 with diabetes, 26 had missing data on the four major perfluorocarbons of interest. The remaining 5270 with diagnoses of diabetes form the primary population for this study.

### 2.4. Measurements of PFAS (PFHxS, PFOA, PFOS, and PFNA)

As referred to in Conway, Innes et al.,<sup>7</sup> perfluoroalkyl substances (PFAS), including PFOA, were analyzed at a single commercial laboratory. Details have been published.<sup>21</sup> Briefly, the protein precipitation extraction method with reverse phase high-performance liquid chromatography/tandem mass spectrometry was utilized for PFAS assays. A triple quadrupole mass spectrometer in pre-selected reaction monitoring mode, monitoring for the *M/Z* transitions of PFAS species with an internal <sup>13</sup>C PFAS standard corresponding to the target compound, was utilized for detection of each PFAS. Four PFAS, PFHxS (perfluorohexane sulfonate), PFOA, PFOS, and PFNA (perfluorononanoic acid) were detected in the serum of over 90% of participants and are the focus of the current study.

### 2.5. Calculation of eGFR

Serum creatinine was measured using a kinetic rate Jaffe method.<sup>23</sup> Estimated glomerular filtration rate was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.<sup>24</sup> Chronic kidney disease was defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m<sup>2</sup>.

### 2.6. Statistical analysis

General linear models were used to test for differences in continuous variables and the chi square test was used to test for differences in categorical data. Logistic regression was used to estimate the relationship of each PFAS with coronary heart disease. Interaction terms that included the PFAS were created by the cross products of the potential effect modifying variable and the addition of 1 to the log of the specific PFAS. The criterion for statistical significance was a two-tailed *p*-value of <0.10 for effect modification and <0.05 otherwise. Statistical analysis was conducted using SAS version 9.4 (Cary, North Carolina).

## 3. Results

### 3.1. Characteristics of the population

Characteristics of the adult C8 Health Study participants with diabetes stratified by CHD status are presented in Table 1. Persons with CHD and diabetes tended to be older, male, marginally more likely to be White, and more likely to have had diabetes for a longer period of time. They were also more likely to have a history of smoking, chronic kidney disease, higher uric acid levels, but tended to have a lower BMI, lower kidney function as measured by eGFR, and lower lipid levels. Median PFHxS and PFNA were slightly lower among those with CHD than among those without CHD.

### 3.2. Association between PFAS and CHD

In analyses controlling for age and sex, each PFAS was inversely associated with CHD (ORs = 0.81 (0.78–0.84) for PFHxS; 0.91 (0.89–0.93) for PFOA; 0.85 (0.82–0.89) for PFOS; and 0.83 (0.78–0.88) for PFOS). Upon further controlling for diabetes duration, a history of smoking, BMI, HDLc, LDLc, WBC count, CRP, eGFR, uric acid, hemoglobin and iron, each PFAS remained inversely associated with CHD, with ORs ranging from 0.72 for PFHxS to 0.90 for PFOA and PFOS, and with all but

**Table 1**

Characteristics of adult (age ≥ 20 years) with diabetes in the C8 Health Population by coronary heart disease status, mean ± SD, median (IQR) or % (n).

Characteristics	Coronary heart disease (n = 1489)	No coronary heart disease (n = 3781)	<i>p</i> -Value
Age, years	64.2 ± 11.0	55.3 ± 13.6	<0.0001
Sex, male	60.1 (895)	45.3 (1714)	<0.0001
Race, White	96.9 (1431)	96.08 (3601)	0.16
Diabetes duration, years <sup>a,b</sup>	8.5 (3.9–16.2)	5.9 (2.9–11.6)	<0.0001
A history of smoking	63.5 (942)	53.0 (2001)	<0.0001
BMI, m/kg <sup>2</sup>	32.6 ± 7.1	33.4 ± 9.9	0.002
eGFR, mL/min/1.73 m <sup>2c</sup>	67.1 ± 22.4	81.3 ± 21.1	<0.0001
Chronic kidney disease	36.4 (524)	15.9 (582)	<0.0001
HDLc, mg/dL	43.1 ± 10.8	46.6 ± 12.5	<0.0001
LDLc, mg/dL	88.8 ± 36.6	102.3 ± 35.8	<0.0001
White blood cell count, ×10 <sup>3</sup> /μL	7.6 ± 4.6	7.6 ± 2.3	0.32
C-reactive protein, mg/L	2.7 (1.2–5.9)	2.9 (1.2–6.4)	0.55
Uric acid, mg/dL	6.4 ± 1.8	5.7 ± 1.6	<0.0001
Hemoglobin, g/dL	13.9 ± 1.6	14.2 ± 1.5	<0.0001
Serum iron, μ/dL	78.0 ± 28.6	78.7 ± 30.4	0.46
<i>Perfluoroalkyl acids</i>			
PFHxS, ng/mL <sup>a</sup>	2.6 (1.7–3.9)	2.8 ± 1.8–4.4	<0.0001
PFOA, ng/mL <sup>a</sup>	28.4 (12.6–74.9)	29.0 (12.7–72.8)	0.52
PFOS, ng/mL <sup>a</sup>	22.0 (13.8–32.1)	21.1 (13.7–31.3)	0.82
PFNA, ng/mL <sup>a</sup>	1.3 (0.9–1.7)	1.4 (1.0–1.8)	<0.0001

PFHxS = perfluorohexane sulfonate PFOA = perfluorooctanoic acid PFOS = perfluorooctane sulfonate PFNA = perfluorononanoic acid.

<sup>a</sup> Natural logarithmically transformed before analysis.

<sup>b</sup> Addition of 1 to each value before being natural logarithmically transformed.

<sup>c</sup> Estimated glomerular filtration rate, CKD-EPI formula.

**Table 2**

Multivariable adjusted association of quintiles perfluoroalkyl acids with coronary heart disease in those with diabetes, odds ratio (OR) and 95% confidence intervals (CI).

	PFHxS OR (95% CI)	PFOA OR (95% CI)	PFOS OR (95% CI)	PFNA OR (95% CI)
a				
PFAS <sup>a,b</sup>	0.72 (0.65–0.79)	0.90 (0.85–0.96)	0.90 (0.81–0.99)	0.89 (0.76–1.03)
b				
PFAS <sup>a,b</sup>				
Q1	Ref	Ref	Ref	Ref
Q2	0.75 (0.58–1.97)	0.92 (0.71–1.18)	0.99 (0.76–1.28)	1.04 (0.80–1.35)
Q3	0.72 (0.56–0.93)	0.86 (0.67–1.11)	0.78 (0.60–1.01)	0.96 (0.74–1.25)
Q4	0.66 (0.51–0.85)	0.74 (0.58–0.96)	0.85 (0.66–1.10)	0.93 (0.71–1.20)
Q5	0.45 (0.34–0.58)	0.73 (0.57–0.94)	0.71 (0.55–0.92)	0.81 (0.62–1.05)
Age	1.05 (1.04–1.06)	1.05 (1.04–1.06)	1.05 (1.04–1.06)	1.05 (1.04–1.05)
Sex, male	1.65 (1.37–2.00)	1.60 (1.32–1.93)	1.62 (1.34–1.96)	1.61 (1.33–1.94)
Diabetes duration	1.01 (1.01–1.02)	1.01 (1.01–1.02)	1.01 (1.01–1.02)	1.01 (1.01–1.02)
A history of smoking	1.39 (1.18–1.64)	1.39 (1.18–1.64)	1.37 (1.16–1.62)	1.38 (1.17–1.63)
BMI	1.00 (0.99–1.01)	1.00 (0.99–1.01)	1.00 (0.99–1.01)	1.00 (1.00–1.01)
HDLc	0.98 (0.97–0.99)	0.98 (0.97–0.99)	0.98 (0.97–0.99)	0.98 (0.97–0.99)
LDLc	0.99 (0.99–1.00)	0.99 (0.99–1.00)	0.99 (0.99–1.00)	0.99 (0.99–1.00)
WBC	1.03 (0.99–1.07)	1.03 (0.99–1.07)	1.03 (0.99–1.06)	1.03 (0.99–1.06)
CRP <sup>b</sup>	1.04 (0.96–1.12)	1.04 (0.97–1.12)	1.05 (0.97–1.13)	1.05 (0.98–1.13)
eGFR <sup>c</sup>	0.99 (0.99–0.99)	0.99 (0.98–0.99)	0.99 (0.98–0.99)	0.99 (0.98–0.99)
Uric acid	1.10 (1.04–1.16)	1.10 (1.04–1.16)	1.10 (1.04–1.16)	1.10 (1.04–1.16)
Hemoglobin	0.93 (0.87–0.99)	0.91 (0.86–0.98)	0.91 (0.86–0.98)	0.91 (0.85–0.97)
Iron	1.00 (1.00–1.01)	1.00 (0.99–1.01)	1.00 (1.00–1.01)	1.00 (1.00–1.01)

BMI = body mass index; HDLc = high density lipoprotein cholesterol; LDLc = low density lipoprotein cholesterol; WBC = white blood cell count; CRP = C-reactive protein ORs for non-transformed continuous variables are expressed as per unit increase in the specified variable; ORs for natural logarithmically transformed data are for natural log increase in that variable.


<sup>a</sup> PFAS, perfluoroalkyl substances. This is the model specific PFAS. For example, for the first model it is PFHxS. The first row shows the multivariable adjusted relationship with each PFAS modeled continuously. PFHxS = perfluorohexane sulfonate PFOA = perfluorooctanoic acid PFOS = perfluoro octane sulfonate PFNA = perfluorononanoic acid.

<sup>b</sup> Natural logarithmically transformed before analysis.

<sup>c</sup> Estimated glomerular filtration rate, CKD-EPI formula

PFNA demonstrating a statistically significant relationship. The multivariable adjusted analyses are presented in Table 2a and Fig. 1. Analyses by quintiles showed a stronger inverse relationship with each increasing quintile of PFAS exposure (Table 2b. Results were similar when stratified by sex (Supplementary Table 1).

As a posthoc analysis, we also investigated the relationship of PFAS among the 49,161 study subjects without diabetes (Table 3). Inverse relationships between each of the PFAS and CHD were also observed among the non-diabetic population, with ORs (95% CIs) ranging from 0.92 (89–97)–0.95 (0.92–0.98). However, as seen in Fig. 1, this



**Fig. 1.** Multivariable association of perfluoroalkyl substances with coronary heart disease, stratified by diabetes status. Solid lines represent persons without diabetes. Dashed lines represent persons with diabetes. Panel a) association of perfluorohexane sulfonate with coronary heart disease; panel b) association of perfluorooctanoic acid with coronary heart disease; panel c) association of perfluorooctane sulfonate with coronary heart disease; panel d) association of perfluorononanoic acid with coronary heart disease. Analyses are adjusted for age, sex, diabetes duration (in persons with diabetes), a history of smoking, BMI, HDLc, LDLc, WBC count, CRP, eGFR, uric acid, hemoglobin, and iron.

**Table 3**  
Multivariable adjusted association of perfluoroalkyl acids with coronary heart disease in those without diabetes (n = 49,161), odds ratio (OR) and 95% confidence intervals (CI).

	PFHxS	PFOA	PFOS	PFNA
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
PFAS <sup>a,b</sup>	0.92 (0.89–0.97)	0.95 (0.92–0.98)	0.93 (0.87–0.98)	0.92 (0.85–0.99)
Age	1.07 (1.07–1.08)	1.07 (1.07–1.08)	1.07 (1.07–1.08)	1.07 (1.07–1.08)
Sex, male	1.21 (1.09–1.35)	1.21 (1.09–1.34)	1.21 (1.09–1.34)	1.20 (1.08–1.34)
A history of smoking	1.84 (1.69–1.99)	1.84 (1.69–2.00)	1.83 (1.68–1.98)	1.83 (1.69–1.99)
BMI	1.01 (1.00–1.01)	1.01 (1.00–1.01)	1.01 (1.00–1.01)	1.01 (1.00–1.01)
HDLc	0.99 (0.99–0.99)	0.99 (0.99–0.99)	0.99 (0.99–0.99)	0.99 (0.99–0.99)
LDLc	0.99 (0.99–0.99)	0.99 (0.99–0.99)	0.99 (0.99–0.99)	0.99 (0.98–0.99)
WBC	1.02 (1.00–1.04)	1.02 (1.00–1.04)	1.02 (1.00–1.04)	1.02 (1.00–1.04)
CRP <sup>b</sup>	1.05 (1.01–1.09)	1.05 (1.01–1.09)	1.05 (1.01–1.09)	1.05 (1.01–1.09)
eGFR <sup>c</sup>	1.00 (0.99–1.00)	1.00 (0.99–1.00)	1.00 (0.99–1.00)	1.00 (0.99–1.00)
Uric acid	1.12 (1.08–1.15)	1.12 (1.08–1.15)	1.12 (1.08–1.15)	1.12 (1.08–1.15)
Hemoglobin	0.96 (0.92–0.99)	0.95 (0.92–0.98)	0.96 (0.92–0.99)	0.95 (0.92–0.99)
Iron	1.00 (1.00–1.00)	1.00 (1.00–1.00)	1.00 (1.00–1.00)	1.00 (1.00–1.00)

BMI = body mass index; HDLc = high density lipoprotein cholesterol; LDLc = low density lipoprotein cholesterol; WBC = white blood cell count CRP = C-reactive protein.

<sup>a</sup> PFAS, perfluoroalkyl substances. This is the model specific PFAS. For example, for the first model it is PFHxS. PFHxS = perfluorohexane sulfonate PFOA = perfluorooctanoic acid PFOS = perfluorooctane sulfonate PFNA = perfluorononanoic acid.

<sup>b</sup> Natural logarithmically transformed before analysis.

<sup>c</sup> Estimated glomerular filtration rate, CKD-EPI formula

relationship appeared to be much stronger for PFHxS among those with diabetes (Fig. 1), though significant multiplicative effect modification was not observed (all *p*-values >0.10).

### 3.3. Controlling for kidney function and stratification by chronic kidney disease

Twenty-two percent of the population had chronic kidney disease. To account for potential reverse causation due to reduced kidney function, in addition to controlling for eGFR we also stratified by chronic kidney disease status. Results tended to be similar in both those with and without CKD (Supplementary Table 2). No significant interaction by CKD with any of the PFAS was observed (*p* interaction all >0.10).

## 4. Discussion

In this large population-based cross-sectional study of over 5000 adults with diabetes, we investigated the relationship of coronary heart disease with PFAS, a group of environmental toxicants. To our knowledge, this is the first study to specifically examine the relation of PFAS with CHD in adults with diabetes. Although PFAS have been linked to a number of adverse health outcomes, including dyslipidemia,<sup>2,3</sup> these compounds have also been inversely associated with other cardiovascular disease risk factors such as CRP<sup>25</sup> and kidney function.<sup>17</sup> In the current study, PFAS showed a significant, inverse relationship with CHD; this association persisted after controlling for kidney function and other potentially confounding factors, and remained after stratification by chronic kidney disease status.

Studies investigating the relationship between PFAS and CHD have yielded inconsistent findings, with the majority showing no association. Winquist and Steenland found no meaningful relationship between PFOA and CHD in their study of a worker cohort that included individuals from our broader population, though there was a suggestion of an inverse relationship.<sup>2</sup> In a rural Swedish male population, Mattsson et al. found no association between PFAS and CHD overall, with the exception of a significant positive relationship between perfluoroheptanoic acid and likelihood of CHD.<sup>23</sup> While reasons for the disparity in findings are unclear, they may in part reflect differences in study design and population.

Although mechanisms by which PFAS may lower risk for CHD are unknown, the inverse association observed in this study may reflect the anti-inflammatory and/or insulin-sensitizing properties of certain PFAS, as well as their potentially high oxygen transport capacity.<sup>13–16</sup> Inflammation is known to contribute to the development of CHD by promoting atherosclerosis and inducing insulin resistance.<sup>26</sup> PFAS, particularly PFOA and PFOS, have been reported to have potent anti-

inflammatory effects. These effects may in part be mediated by activation of peroxisome proliferator-activated receptors (PPARs),<sup>27,28</sup> which play an important role in lipid and glucose homeostasis and have anti-atherosclerotic properties,<sup>29,30</sup> including the suppression of vascular inflammation and oxidative stress.<sup>29</sup> CRP is another inflammatory marker generally associated with increased CHD risk; however, CRP has been shown to be inversely related to PFAS.<sup>25</sup> Thus, down regulation of CRP may be another mechanism by which PFAS are associated with a lower likelihood of CHD in our population; reduction of CVD risk factors such as inflammation may partly explain the inverse relationship we observed between PFAS and CHD. Nevertheless, controlling for inflammatory markers such as CRP and WBC count did not eliminate the inverse relationship between PFAS and CHD in our population.

PFAS belong to a broader class of compounds called perfluorocarbons. Perfluorocarbons are hydrogen carbon chains in which the hydrogen atoms have been replaced by fluorine. The fluorine substitution of hydrogen makes perfluorocarbons highly efficient oxygen carriers, as has been shown by some perfluorocarbon emulsions such as perfluorooctyl bromide, with peak oxygen solubility reported to be 25 times greater than either blood or water.<sup>13,14</sup> Another possible mechanism by which PFAS may decrease risk of CHD is by reducing vascular hypoxia. Evidence suggests that hypoxia is a trigger of inflammation and apoptosis in atherosclerosis.<sup>31,32</sup> Myocardial hypoxia is also the cause of myocardial infarction.<sup>33</sup> It may be possible that PFAS are protective against atherosclerosis by mitigating hypoxia-induced inflammation and oxidative stress and hypoxia-induced myocardial infarction. Additionally, persons with an already compromised oxygen carrying capacity may suffer from greater harm if they have a myocardial infarction, which further compromises myocardial oxygenation; conversely, someone with superior oxygen carrying capacity may be relatively protected against myocardial infarction.

We cannot explain the much stronger inverse relationship of PFHxS with CHD than for the other PFAS, nor why this was only observed in the diabetic population. This strong inverse relationship was observed when PFHxS was modeled linearly as a continuous variable and when grouped into quintiles. In an animal toxicity study of PFHxS by the Minnesota Department of Health,<sup>34</sup> PFHxS exposure among rats resulted in a decrease in body weight, cholesterol levels and an increase in prothrombin time, all factors likely to lower the risk of CHD.<sup>34</sup> BMI and lipids were included in our models and did not explain the relationship between PFHxS and CHD. While we cannot fully explain why the strong inverse relationship of PFHxS exposure with CHD was only observed among those with diabetes in our population, this may in part reflect the more generalized chronic hypoxia among persons with diabetes, coupled with the longer half-lives of the sulfur containing PFAS.<sup>35,36</sup>

Consistent with this explanation, of the four PFAS investigated, we have previously observed the strongest inverse relationship with PFHxS, followed by PFOS, for the likelihood of having diabetes in our prior investigation of PFAS exposure and diabetes risk.<sup>7</sup> Though this inverse relationship was particularly pronounced for Type 1 diabetes, a condition that has been characterized as a state of chronic hypoxia, a similar finding for Type 2 diabetes was also reported by Donat-Vargas et al.<sup>37</sup>

Strengths of this study include the population-based design, the large sample size of adults who reported a diagnosis of diabetes, and the high study participation rate. As noted above, this is the first study to specifically investigate the relation of PFAS levels with CHD in adults with diabetes. Additional strengths include our ability to evaluate persistent biomarkers of PFAS exposure obtained concurrently with survey information regarding diagnosis of diabetes, CHD, and other conditions, the measurement of a broad array of biomarkers and other clinical data, and the extensive information available on potential confounders. We were also able to assess the association of PFAS which CHD by chronic kidney disease status, helping to clarify the possible modifying effects of this condition.

Our study also has several limitations. First, because of the cross-sectional nature of the data, we cannot draw conclusions regarding causal associations and cannot rule out the possibility of survival bias. For example, it is possible that sicker persons with CHD and higher prior PFAS exposure had already died. In a cross-sectional study, we were unable to assess this; however, prospective data on PFAS and CHD has failed to show an association with the contaminants.<sup>11</sup> It remains possible that the observed associations are due to chance; however, this is unlikely given that the relationships of PFAS with CHD remained consistently robust after adjustment for multiple covariates. Unmeasured confounding might also contribute to our findings, although our ability to control for a large number of both known and potential risk factors for CHD renders this possibility less probable. Finally, for the primary analyses, ascertainment of diabetes was based on participant-reported physician diagnosis, which may have introduced misclassification bias. However, agreement between self-report and medical record-verified data for diabetes in this study population was good (over 80%).<sup>9</sup>

In conclusion, in this cross-sectional analysis of over 5000 adults with diabetes, PFAS demonstrated significant inverse relationships with CHD that were not modified by the presence of chronic kidney disease. While our results should not be interpreted as suggesting that exposure to these environmental contaminants is beneficial, these findings may, if confirmed in future studies, may provide new physiological understanding of CHD prevention strategies.

## Data availability

The C8 Health Project data used to support the findings of this study have not been made available because of court mandated order related to the legal settlement, which resulted in the C8 Health Project, that only West Virginia University Investigators may access the data.

## Funding statement

This work was supported in part by the National Institutes of Health, United States grant U54GM1049 to the West Virginia University CTSI.

## Acknowledgments

KK wrote the manuscript. RH analyzed the data and contributed to the discussion. KEI critically reviewed the manuscript for scientific content and contributed to the discussion. BNC designed the study, analyzed the data, contributed to the discussion and critically reviewed the manuscript for scientific content. Dr. Baqiyah N. Conway is the guarantor of this work and, as such, had full access to all of the data in the study and takes full responsibility for the integrity of the data and

the accuracy of the data analysis. This work was presented in part at the 2015 American Heart Association's Epidemiology and Prevention | Lifestyle and Cardiometabolic Health, New Orleans, LA.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jdiacomp.2019.02.004>.

## References

- Post GB, Gleason JA, Cooper KR. Key scientific issues in developing drinking water guidelines for perfluoroalkyl acids: contaminants of emerging concern. *PLoS Biol* 2017;15: e2002855. <https://doi.org/10.1371/journal.pbio.2002855>. [Epub 2017/12/21. PubMed PMID: 29261653; PMCID: PMC5737881].
- Winquist A, Steenland K. Modeled PFOA exposure and coronary artery disease, hypertension, and high cholesterol in community and worker cohorts. *Environ Health Perspect* 2014;122:1299-305. <https://doi.org/10.1289/ehp.1307943>. [Epub 2014/09/27. PubMed PMID: 25260175; PMCID: PMC4256699].
- Starling AP, Engel SM, Whitworth KW, Richardson DB, Stuebe AM, Daniels JL, et al. Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study. *Environ Int* 2014;62:104-12. <https://doi.org/10.1016/j.envint.2013.10.004>. [Epub 2013/11/06. PubMed PMID: 24189199; PMCID: PMC3870471].
- Qin XD, Qian Z, Vaughn MG, Huang J, Ward P, Zeng XW, et al. Positive associations of serum perfluoroalkyl substances with uric acid and hyperuricemia in children from Taiwan. *Environ Pollut* 2016;212:519-24. <https://doi.org/10.1016/j.envpol.2016.02.050>. [Epub 2016/03/14. PubMed PMID: 26970855].
- Karnes C, Winquist A, Steenland K. Incidence of type II diabetes in a cohort with substantial exposure to perfluorooctanoic acid. *Environ Res* 2014;128:78-83. <https://doi.org/10.1016/j.envres.2013.11.003>. [Epub 2013/12/05. PubMed PMID: 24299613].
- Lind L, Zethelius B, Salihovic S, van Bavel B, Lind PM. Circulating levels of perfluoroalkyl substances and prevalent diabetes in the elderly. *Diabetologia* 2014;57:473-9. <https://doi.org/10.1007/s00125-013-3126-3>. [Epub 2013/12/18. PubMed PMID: 24337155].
- Conway B, Innes KE, Long D. Perfluoroalkyl substances and beta cell deficient diabetes. *J Diabetes Complications* 2016;30:993-8. <https://doi.org/10.1016/j.jdiacomp.2016.05.001>. [Epub 2016/06/18. PubMed PMID: 27311784; PMCID: PMC5556924].
- Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. *Environ Health Perspect* 2010;118:686-92. <https://doi.org/10.1289/ehp.0901584>. [Epub 2010/01/22. PubMed PMID: 20089479; PMCID: PMC2866686].
- MacNeil J, Steenland NK, Shankar A, Ducatman A. A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). *Environ Res* 2009;109:997-1003. <https://doi.org/10.1016/j.envres.2009.08.002>. [Epub 2009/09/11. PubMed PMID: 19740462].
- Sun Q, Zong G, Valvi D, Nielsen F, Coull B, Grandjean P. Plasma concentrations of perfluoroalkyl substances and risk of type 2 diabetes: a prospective investigation among U.S. women. *Environ Health Perspect* 2018;126: 037001. <https://doi.org/10.1289/ehp2619>. [Epub 2018/03/03. PubMed PMID: 29498927].
- Mattsson K, Rignell-Hydbom A, Holmberg S, Thelin A, Jonsson BA, Lindh CH, et al. Levels of perfluoroalkyl substances and risk of coronary heart disease: findings from a population-based longitudinal study. *Environ Res* 2015;142:148-54. <https://doi.org/10.1016/j.envres.2015.06.033>. [Epub 2015/07/06. PubMed PMID: 26142720].
- Christensen KY, Raymond M, Thompson BA, Anderson HA. Perfluoroalkyl substances in older male anglers in Wisconsin. *Environ Int* 2016;91:312-8. <https://doi.org/10.1016/j.envint.2016.03.012>. [Epub 2016/03/24. PubMed PMID: 27003842].
- Hancock JB, Davidson S, Guinn C, Zachary R. Using liquid ventilation to improve lung function in patients with respiratory distress syndrome: a comprehensive review of the literature. *AANA J* 2004;72:218-24. [Epub 2004/06/24. PubMed PMID: 15208970].
- Hosgood SA, Nicholson ML. The role of perfluorocarbon in organ preservation. *Transplantation* 2010;89:1169-75. <https://doi.org/10.1097/TP.0b013e3181da6064>. [Epub 2010/04/16. PubMed PMID: 20393403].
- Atias S, Mizrahi SS, Shaco-Levy R, Yussim A. Preservation of pancreatic tissue morphology, viability and energy metabolism during extended cold storage in two-layer oxygenated University of Wisconsin/perfluorocarbon solution. *Isr Med Assoc J* 2008;10:273-6. [Epub 2008/06/14. PubMed PMID: 18548980].
- Reznik ON, Bagnenko SF, Loginov IV, Iljina VA, Ananyev AN, Moysyuk YG. The use of oxygenated perfluorocarbon emulsion for initial in situ kidney perfusion. *Transplant Proc* 2008;40:1027-8. <https://doi.org/10.1016/j.transproceed.2008.03.053>. [Epub 2008/06/17. PubMed PMID: 18555106].
- Conway B, Badders A, Costacou T, Arthur J, Innes K. Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes. *Diabetes Metab Syndr Obes* 2018;11:707-16. <https://doi.org/10.2147/DMSO.S173809>. [PMCID: PMC6244585].
- Fu Q, Colgan SP, Shelley CS. Hypoxia: the force that drives chronic kidney disease. *Clin Med Res* 2016;14:15-39. <https://doi.org/10.3121/cmr.2015.1282>. [Epub 2016/02/06. PubMed PMID: 26847481; PMCID: PMC4851450].
- Fine LG, Orphanides C, Norman TJ. Progressive renal disease: the chronic hypoxia theory. *Kidney Int Suppl* 1998;65:574-8.

20. Ow CPC, Ngo JP, Ullah MM, Hilliard LM, Evans RG. Renal hypoxia in kidney disease: cause or consequence? *Acta Physiol (Oxf)* 2018;222, e12999, <https://doi.org/10.1111/apha.12999>. [Epub 2017/11/22. PubMed PMID: 29159875].
21. Frisbee SJ, Brooks Jr AP, Maher A, Flensburg P, Arnold S, Fletcher T, et al. The C8 health project: design, methods, and participants. *Environ Health Perspect* 2009;117:1873–82, <https://doi.org/10.1289/ehp.0800379>. [Epub 2010/01/06. PubMed PMID: 20049206; PMCID: PMC2799461].
22. Steenland K, Tinker S, Shankar A, Ducatman A. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. *Environ Health Perspect* 2010;118:229–33, <https://doi.org/10.1289/ehp.0900940>. [Epub 2010/02/04. PubMed PMID: 20123605; PMCID: PMC2831922].
23. Cain L, Shankar A, Ducatman AM, Steenland K. The relationship between serum uric acid and chronic kidney disease among Appalachian adults. *Nephrol Dial Transplant* 2010;25:3593–9, <https://doi.org/10.1093/ndt/gfq262>. [Epub 2010/05/27. PubMed PMID: 20501458; PMCID: PMC2980994].
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro III AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604–12. [Epub 2009/05/06. PubMed PMID: 19414839; PMCID: PMC2763564].
25. Genser B, Teles CA, Barreto ML, Fischer JE. Within- and between-group regression for improving the robustness of causal claims in cross-sectional analysis. *Environ Health* 2015;14:60, <https://doi.org/10.1186/s12940-015-0047-2>. [Epub 2015/07/15. PubMed PMID: 26159541; PMCID: PMC4702298].
26. Montero-Vega MT. The inflammatory process underlying atherosclerosis. *Crit Rev Immunol* 2012;32:373–462. [Epub 2013/01/24. PubMed PMID: 23339672].
27. Mollenhauer MA, Bradshaw SG, Fair PA, McGuinn WD, Peden-Adams MM. Effects of perfluorooctane sulfonate (PFOS) exposure on markers of inflammation in female B6C3F1 mice. *J Environ Sci Health A Tox Hazard Subst Environ Eng* 2011;46:97–108, <https://doi.org/10.1080/10934529.2011.532418>. [Epub 2010/12/21. PubMed PMID: 21170772].
28. DeWitt JC, Shnyra A, Badr MZ, Loveless SE, Hoban D, Frame SR, et al. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. *Crit Rev Toxicol* 2009;39:76–94, <https://doi.org/10.1080/10408440802209804>. [Epub 2008/09/20. PubMed PMID: 18802816].
29. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. *Biochim Biophys Acta* 2007;1771:972–82, <https://doi.org/10.1016/j.bbali.2007.04.021>. [Epub 2007/07/17. PubMed PMID: 17631413; PMCID: PMC2083576].
30. Qi ZG, Zhao X, Zhong W, Xie ML. Osthole improves glucose and lipid metabolism via modulation of PPARalpha/gamma-mediated target gene expression in liver, adipose tissue, and skeletal muscle in fatty liver rats. *Pharm Biol* 2016;54:882–8, <https://doi.org/10.3109/13880209.2015.1089295>. [Epub 2015/10/13. PubMed PMID: 26455539].
31. Bitto A, De Caridi G, Polito F, Calo M, Irrera N, Altavilla D, et al. Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques. *J Vasc Surg* 2010;52:1015–21, <https://doi.org/10.1016/j.jvs.2010.05.116>. [Epub 2010/08/20. PubMed PMID: 20719466].
32. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. *J Am Coll Cardiol* 2008;51:1258–65, <https://doi.org/10.1016/j.jacc.2007.12.025>. [Epub 2008/03/29. PubMed PMID: 18371555].
33. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. *Circulation* 2007;116:2634–53, <https://doi.org/10.1161/circulationaha.107.187397>. [Epub 2007/10/24. PubMed PMID: 17951284].
34. Perfluorohexane sulfonate. Environment Health Division HRAU. Minnesota: Minnesota Department of Health; 2009.
35. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. *Environ Health Perspect* 2007;115:1298–305, <https://doi.org/10.1289/ehp.10009>. [Epub 2007/09/07. PubMed PMID: 17805419; PMCID: PMC1964923].
36. Li Y, Fletcher T, Mucs D, Scott K, Lindh CH, Tallving P, et al. Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water. *Occup Environ Med* 2018;75:46–51, <https://doi.org/10.1136/oemed-2017-104651>. [Epub 2017/11/15. PubMed PMID: 29133598; PMCID: PMC5749314].
37. Donat-Vargas C, Bergdahl IA, Tornevi A, Wennberg M, Sommar J, Kiviranta H, et al. Perfluoroalkyl substances and risk of type II diabetes: a prospective nested case-control study. *Environ Int* 2019;123:390–8, <https://doi.org/10.1016/j.envint.2018.12.026>. [Epub 2019/01/10. PubMed PMID: 30622063].